- Global Pharma News & Resources

4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

DGAP-News: 4SC AG / Key word(s): Conference

21.10.2019 / 07:30
The issuer is solely responsible for the content of this announcement.

4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

  • Poster presentations at the 1st International Symposium on Merkel Cell Carcinoma 21-22 October 2019, Tampa, Florida, USA

Planegg-Martinsried, Germany, 21 October 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced that a poster entitled: The preclinical rationale and clinical design for the combination of domatinostat with avelumab in Merkel Cell Carcinoma patients: the MERKLIN 1 and MERKLIN 2 studies by Dr. René Bartz will be presented at the 1st International Symposium on Merkel Cell Carcinoma 21-22 October 2019, Tampa, Florida, USA. The poster will be available on 4SC's website after the presentation.

- Press release ends -


Further information

About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 30 September 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

About domatinostat

Domatinostat is an orally administered small molecule class I selective HDAC inhibitor. It strengthens the body's own anti-tumor immune response, influences the tumor and tumor microenvironment, making the tumor more visible to the immune system and facilitating the infiltration of immune cells into the tumor.

Domatinostat has been investigated in a Phase I study in 24 heavily pretreated patients with several types of advanced hematologic cancers and was well tolerated. Positive signs of anti-tumor efficacy were also observed; with one complete remission (28 months) and one partial responder (8 months).

In addition to its therapeutic potential in cancer monotherapy, 4SC is evaluating domatinostat's capacity as a partner in combination therapies, specifically in the immuno-oncology area. In this respect, 4SC initiated a Phase Ib/II study of domatinostat in combination with the anti-PD-1 checkpoint inhibitor pembrolizumab in patients with advanced-stage melanoma from which initial data was presented at ESMO 2019. A second Phase II study of domatinostat in combination with the anti-PD-L1 checkpoint inhibitor avelumab in patients with advanced-stage microsatellite-stable gastrointestinal cancer is currently being conducted by Prof. David Cunningham at The Royal Marsden NHS Foundation Trust in London, UK.

4SC also plans to advance domatinostat into a number of other studies in combination with a checkpoint inhibitor, including in patients with advanced Merkel-cell carcinoma (MCC), in 2019 and 2020.

About the MERKLIN clinical studies

The Phase II open label, multicenter MERKLIN 2 and 1 clinical studies will be initiated by 4SC in Q4 2019 and Q1, 2020 respectively and will evaluate the combination of domatinostat and the PD-L1 checkpoint inhibitor avelumab in patients with advanced Merkel-cell carcinoma.

About merkel cell carcinoma

Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer of the skin prone with a high risk of metastasis and whose incidence has tripled over the last 20 years. Risk factors for MCC include sun exposure, fair skin, age over 50 and a weakened immune system. There are few effective treatments for MCC, but immunotherapy with checkpoint blockade is approved in both the EU, US and Australia based on positive data in a number of clinical studies.

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.


+49 89 700763-0

21.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Phone: +49 89 700763-0
Fax: +49 89 700763-29
ISIN: DE000A14KL72
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 892503

End of News DGAP News Service

Editor Details

Last Updated: 21-Oct-2019